In a phase 3 trial of lecanemab, a monoclonal antibody to the notorious amyloid-beta fibrils that are pathognomonic of Alzheimer’s disease, recipients achieved a statistically (though probably not clinically) significant reduction in severity of cognitive decline at 18 months, and it’s making headlines as the first therapy ever to even make a dent in this frequently devastating disease.
Citation(s)
- van Dyck, N Engl J Med 2022